Table 2.
Recipient, donor and transplant characteristics
| Recipient | |
| Age (years), mean ± SD | 48.2 ± 14.8 (range 18–75) |
| Race | |
| Non-AA | 106 (84.8) |
| AA | 19 (14.6) |
| Males | 79 (63.2) |
| BMI (kg/m2), mean ± SD | 29.0 ± 5.4 |
| BSA (kg/m2), mean ± SD | 1.98 ± 0.26 |
| Cause of renal disease | |
| Congenital/familial | 8 (6.4) |
| PKD | 14 (11.2) |
| Glomerular | 28 (22.4) |
| Hypertension | 17 (13.6) |
| Diabetes | 39 (31.2) |
| Other | 19 (15.2) |
| Dialysis vintage | |
| Preemptive | 28 (22.4) |
| Dialysis 0–2 years | 60 (48.0) |
| Dialysis >2 years | 37 (29.6) |
| Calculated panel reactive antibody >20 | 22 (17.6) |
| Previous transplantation | 6 (4.8) |
| Induction (thymoglobulin) | 106 (85) |
| No induction | 19 (15) |
| Maintenance immunosuppression | |
| Tacrolimus, mycophenolate mofetil, steroid | 121 (96.8) |
| Tacrolimus, mycophenolate mofetil | 1(0.8) |
| Tacrolimus, everolimus, steroid | 2(1.6) |
| Cyclosporine, mycophenolate, steroid | 1(0.8) |
| Transplantation | |
| Living donor | 84 (67.2) |
| Cold ischemia time, median (IQR) | 3.0 (1.7–10.0) |
| HLA mismatch | |
| 0–2 | 30 (24.0) |
| 3–4 | 53 (42.0) |
| 5–6 | 42 (33.6) |
| Donor | |
| Age (years), mean ± SD | 40.2 ± 12.4 (range 7–64) |
| Race | |
| Non-AA | 111 (88.8) |
| AA | 14 (11.2) |
| Males | 53 (42.4) |
| BMI (kg/m2), mean ± SD | 26.9 ± 5.4 |
| BSA (kg/m2), mean ± SD | 1.86 ± 0.28 |
Values presented as n (%) unless stated otherwise. Diseases included congenital/familial (prune belly, renal hypoplasia, medullary cystic disease, renal agenesis, congenital obstructive uropathy), glomerular (IgA, FSGS, membranous, SLE, Wegner’s granulomatosis, Alport’s, chronic glomerulonephritis, Henoch–Schöenlein purpura) and other (lithium toxicity, pyelonephritis, obstructive uropathy, interstitial nephropathy, unknown).
AA, African American; BMI, body mass index; PKD, polycystic kidney disease; HLA, human leukocyte antigen; FSGS, focal segmental glomerulosclerosis; SLE, systemic lupus erythematosus.